Boston Scientific Corporation (NYSE:BSX)’s VITALIO vital for apnea identification
On 26 June, the very first patient implant of Boston Scientific Corporation (NYSE: BSX)’s VITALIOTM was performed at ZGT Hengelo in the Netherlands. VITALIO has a very comprehensive suite of features. These are designed for optimization of cardiac pacing. In addition to this, the pacemaker features the company’s innovative AP ScanTM technology which has been designed to help doctors identify patients suffering from severe sleep apnea. Leaving this breathing condition untreated can lead to and increased risk of heart attack, high blood pressure, stroke or heart failure.
It is possible to gain an insight into the sleep apnea status of a patient, with VITALIO. Not only does it help physicians identify which patients might be suffering from this disorder, but it also helps them understand if the sleep apnea treatments that have been prescribed, are actually taking effect.
What is sleep apnea?
Sleep apnea is a chronic condition that disrupts a person’s sleep. When there is pause in breathing or even shallowness, the person tends to transition from a deep sleep into a lighter one which affects sleep quality. Breathing pauses may last between a few seconds to a few minutes. They can occur 30 times or even more over an hour. Typically, normal breathing restarts with a loud choking or snorting sound. Consequently this leads to tiredness during the day and is the primary cause of day-time sleepiness. More often than not, this condition goes undiagnosed and doctors are not generally able to detect it in the course of routine check-up’s and blood tests don’t help in diagnosing it either.
Most people who suffer from sleep apnea don’t even know they have it as it occurs only when a person is asleep. It is generally a bed partner or a family member who first notices sleep apnea signs. Sleep apnea is a very common comorbidity in patients suffering from cardiovascular disease. It affects around 60% of those patients and almost 80% tend to remain undiagnosed. Sleep apnea is directly linked to a doubled heart failure morbidity or mortality risk and a quadrupled atrial fibrillation risk. Sleep apnea patients will benefit a great deal from the VITALIO launch.